4/A: CORCEPT CDO Amends Insider Trading Report

Corcept Therapeutics' Chief Development Officer, William Guyer, filed an amended Form 4 to correct details regarding past stock transactions and ownership.

Summary

• William Guyer, Chief Development Officer of Corcept Therapeutics Inc. (CORT), filed an amended Form 4 to correct previously reported beneficial ownership details.
• The amendment clarifies that 5,287 shares of common stock were transferred without consideration from Guyer directly to The Lake Bainwood Living Trust on November 17, 2025. This transaction was inadvertently omitted from prior filings.
• It also corrects the ownership form for a sale of 4,500 shares on November 25, 2025, stating these shares were held indirectly by The Lake Bainwood Living Trust, not directly as previously reported.
• The 4,500 shares were sold at a weighted average price of $80.9045, with actual sale prices ranging from $80.81 to $81.085 per share.
• Following these transactions, Guyer indirectly beneficially owns 787 shares through The Lake Bainwood Living Trust.

Sentiment

Score: 5

Explanation: Neutral. The filing corrects past reporting errors, which is a positive for compliance, but the initial error is a minor negative. No impact on company operations or financial performance is indicated.

Positives

• The company and its officer are proactively correcting reporting errors, demonstrating commitment to regulatory compliance and transparency.

Negatives

• Initial reporting errors occurred, requiring an amendment to correct previously filed information.

Risks

• Potential for scrutiny from regulatory bodies regarding the accuracy and timeliness of insider trading reports, although this amendment aims to rectify such issues.

Future Outlook

NA

Management Comments

• This transaction was inadvertently omitted from previous filings.
• Transfer of shares without consideration to The Lake Bainwood Living Trust.
• Represents the shares held by The Lake Bainwood Living Trust of which the Reporting Person is a co-trustee.
• Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $80.81 to $81.085 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
• On November 26, 2025, the Reporting Person filed a Form 4 that inadvertently reported that the 4,500 shares sold were held directly. By this amendment, the Reporting Person corrects such report by reporting that the shares sold were held indirectly by The Lake Bainwood Living Trust of which the Reporting Person is a co-trustee as a result of the transfer that occurred on November 17, 2025, now reported in this amendment.

Industry Context

This filing is a routine amendment to an insider trading report and does not provide information related to broader industry trends or competitive landscape for the pharmaceutical sector.

Corporate Governance

Related Party Transactions

• Transfer of 5,287 shares without consideration to The Lake Bainwood Living Trust, of which the reporting person (William Guyer) is a co-trustee. This is a transaction between the officer and a trust he co-manages.

Stakeholder Impact

• Shareholders: Increased transparency regarding insider transactions, ensuring accurate records of officer holdings. No direct financial impact from the amendment itself.
• Regulatory Authorities: Demonstrates compliance and responsiveness to reporting requirements by correcting errors.

Next Steps

• The Issuer can provide exact share sale price details upon request.

Key Dates

Keywords

Corcept Therapeutics, CORT, Form 4/A, Insider Trading, Beneficial Ownership, William Guyer, Chief Development Officer, Stock Transaction, SEC Filing, Corporate Governance